[{"address1": "9390 Towne Centre Drive", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 779 3100", "website": "https://poseida.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.", "fullTimeEmployees": 337, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark J. Gergen J.D.", "age": 60, "title": "Executive Chairman of the Board", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 961797, "exercisedValue": 0, "unexercisedValue": 174418}, {"maxAge": 1, "name": "Dr. Kristin  Yarema Ph.D.", "age": 52, "title": "President, CEO & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 711986, "exercisedValue": 0, "unexercisedValue": 61459}, {"maxAge": 1, "name": "Ms. Johanna M. Mylet CPA", "age": 35, "title": "Chief Financial Officer", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Loren  Wagner", "title": "Chief Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristin  Martin", "title": "Chief People & Administration Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Chapman", "title": "Senior VP of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Harry J. Leonhardt Esq., J.D.", "age": 66, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 630233, "exercisedValue": 0, "unexercisedValue": 25579}, {"maxAge": 1, "name": "Dr. Devon J. Shedlock Ph.D.", "title": "Chief Scientific Officer of Cell Therapy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa  Portale", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey  W. Winkelman J.D., Ph.D.", "title": "Senior VP & Chief Patent Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.78, "open": 2.85, "dayLow": 2.64, "dayHigh": 2.91, "regularMarketPreviousClose": 2.78, "regularMarketOpen": 2.85, "regularMarketDayLow": 2.64, "regularMarketDayHigh": 2.91, "beta": 0.507, "forwardPE": -1.4728261, "volume": 355826, "regularMarketVolume": 355826, "averageVolume": 427648, "averageVolume10days": 322670, "averageDailyVolume10Day": 322670, "bid": 2.68, "ask": 2.73, "bidSize": 100, "askSize": 500, "marketCap": 263232880, "fiftyTwoWeekLow": 1.83, "fiftyTwoWeekHigh": 4.27, "priceToSalesTrailing12Months": 2.9756606, "fiftyDayAverage": 3.0764, "twoHundredDayAverage": 3.037325, "currency": "USD", "enterpriseValue": 115835088, "profitMargins": -1.2748101, "floatShares": 64350857, "sharesOutstanding": 97133904, "sharesShort": 3672239, "sharesShortPriorMonth": 5215939, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0378, "heldPercentInsiders": 0.2774, "heldPercentInstitutions": 0.55373, "shortRatio": 7.58, "shortPercentOfFloat": 0.0523, "bookValue": 0.626, "priceToBook": 4.3290734, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -112772000, "trailingEps": -1.18, "forwardEps": -1.84, "pegRatio": -0.73, "enterpriseToRevenue": 1.309, "enterpriseToEbitda": -1.026, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "PSTX", "underlyingSymbol": "PSTX", "shortName": "Poseida Therapeutics, Inc.", "longName": "Poseida Therapeutics, Inc.", "firstTradeDateEpochUtc": 1594387800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "291e20e1-54d3-33de-96cd-b23bf8be3533", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.71, "recommendationMean": 1.6, "recommendationKey": "buy", "totalCash": 237812000, "totalCashPerShare": 2.449, "ebitda": -112858000, "totalDebt": 83653000, "quickRatio": 2.443, "currentRatio": 2.483, "totalRevenue": 88462000, "debtToEquity": 137.549, "revenuePerShare": 0.93, "returnOnAssets": -0.25536, "returnOnEquity": -1.15004, "freeCashflow": -751000, "operatingCashflow": 2459000, "revenueGrowth": 0.298, "grossMargins": -0.77228, "ebitdaMargins": -1.2757801, "operatingMargins": -1.22265, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]